UnitedHealth Group Incorporated (UNH)
Stay Ahead of the Game With UnitedHealth (UNH) Q3 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for UnitedHealth (UNH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
UNH heads into Q3 with investors focused on whether medical-cost gains can hold as Medicare Advantage margins improve without deeper member losses.
Here's Why UnitedHealth Group (UNH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
UnitedHealth: The Upside Is Gone
UnitedHealth Group (UNH) has rebounded from $300 to $440-$450, with fundamental recovery in margins, Medicare Advantage, and Optum Health now largely realized. I now rate UNH a Sell, as the risk/reward has flipped: valuation offers little margin of safety, and the market prices in recovery and future growth. Further upside depends on flawless execution amid persistent medical cost inflation and ongoing challenges in Commercial and Medicaid segments.
UNH Exits Select Medicare Advantage Plans for 2027 Amid Cost Pressure
UnitedHealth is exiting select Medicare Advantage plans for 2027 as rising medical costs pressure profitability, reshaping its membership mix.
Texas AG Paxton Launches Investigation Into UnitedHealth Group
Texas Attorney General Ken Paxton has sent civil investigative demands to the company to collect evidence around potential violations of the Texas Deceptive Trade Practices Act, according to his office.
Is It Worth Investing in UnitedHealth (UNH) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
UnitedHealth Group: Getting Cheaper And Cheaper
UnitedHealth Group (UNH) remains a Buy, with fundamentals improving and valuation at a decade low P/E of 19.95 despite peer discounts. Key Q3 focus areas include commercial cost trends, star ratings, cash flow guidance, and Optum's performance amid shrinking insured books. UNH's FCF yield is at a nine-year high (7.1%), and its robust revenue CAGR and margins highlight scale advantages.
UnitedHealth Group (UNH) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $371.9, denoting a +1.83% move from the preceding trading day.
UnitedHealth: The Recovery Is Working, The Stock Isn't
UnitedHealth is demonstrating tangible margin recovery, especially in Medicare and Optum Health, though Commercial remains a weak spot. The company raised operating earnings guidance and improved its medical care ratio, signaling progress despite ongoing challenges in Medicaid and Commercial segments. At 17.8x NTM P/E, UnitedHealth is reasonably valued; the upside relies on continued margin normalization rather than top-line growth or multiple expansion.
UnitedHealth Stock Has Gone Nowhere for Five Years. Its Dividend Has Not
UnitedHealth shareholders spent five years waiting for a stock that barely budged, yet something inside the company kept growing the whole time.
